Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
ProMIS Neurosciences ( (PMN) ) has provided an announcement.
On November 24, 2025, ProMIS Neurosciences announced a one-for-twenty-five reverse stock split of its common shares, which will take effect on November 28, 2025. This decision, approved by the board of directors, aims to address the company’s non-compliance with Nasdaq’s minimum bid price requirement, potentially enhancing the market price of its shares and ensuring continued listing on the Nasdaq Capital Market.
The most recent analyst rating on (PMN) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on ProMIS Neurosciences stock, see the PMN Stock Forecast page.
Spark’s Take on PMN Stock
According to Spark, TipRanks’ AI Analyst, PMN is a Underperform.
ProMIS Neurosciences faces significant financial hurdles, with no current revenue and ongoing operational losses, leading to a weak overall financial performance. The technical analysis indicates the stock is under pressure, and the valuation reflects challenges with a negative P/E ratio. While recent corporate events show promise in terms of future growth potential, they do not offset the immediate financial challenges. The overall score reflects the need for cautious optimism, as the company must improve its financials and achieve sustainable revenue generation.
To see Spark’s full report on PMN stock, click here.
More about ProMIS Neurosciences
ProMIS Neurosciences Inc. is a clinical-stage biotechnology company focused on developing therapeutic antibodies and vaccines targeting toxic oligomers associated with neurodegenerative diseases such as Alzheimer’s disease, amyotrophic lateral sclerosis, frontotemporal dementia, multiple system atrophy, and Parkinson’s Disease. The company utilizes its proprietary EpiSelect™ technology to identify novel targets on misfolded proteins.
Average Trading Volume: 1,450,961
Technical Sentiment Signal: Strong Sell
Current Market Cap: $22.6M
See more data about PMN stock on TipRanks’ Stock Analysis page.